ABSTRACT
Pyruvate kinase is an essential enzyme in the anaerobic glycolytic pathway of the erythrocyte.
The clinical presentation of this enzyme deficiency is due to the haemolytic process that results
from the inability of erythrocytes to generate sufficient ATP. Although pyruvate kinase and
glucose-6-phosphate dehydrogenase deficiencies comprise more than 90% of all reported red cell
enzyme disorders worldwide, the epidemiology of the disease in South Africa is unknown and
there is no assay for pyruvate kinase activity currently being used in South Africa. This report
describes the implementation of screening and quantitative assays for pyruvate kinase activity in
the Red Cell Membrane Unit at the University of the Witwatersrand Medical School / NHLS.
The accuracy, precision and reproducibility of the assay were verified. Furthermore, a patient
with pyruvate kinase deficiency was confirmed and found to have 15% of normal enzyme
activity at 37oC. The genetic abnormality was identified as a homozygous G1529A point
mutation in exon 11 of the pyruvate kinase gene and to the candidate’s knowledge is the first
mutation described in a South African kindred. The patient’s mother was heterozygous for the
G1529A mutation and demonstrated an enzyme activity of 58% of normal at 37oC.
| Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:wits/oai:wiredspace.wits.ac.za:10539/4950 |
| Date | 10 June 2008 |
| Creators | Durand, Pierre Marcel |
| Source Sets | South African National ETD Portal |
| Language | English |
| Detected Language | English |
| Type | Thesis |
| Format | 103330 bytes, 670899 bytes, application/pdf, application/pdf, application/pdf, application/pdf |
Page generated in 0.0571 seconds